Oncolytics completes enrollment in cancer combination therapy study
Oncolytics Biotech, a biopharmaceutical company, has completed patient enrollment in its UK clinical trial to evaluate the anti-tumor effects of intravenous administration of Reolysin in combination with gemcitabine
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.